SCHEMBL6920592

SCHEMBL6920592

O=c1c2ccc(-c3ccccn3)cc2nc2n1CC1CC21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.38
DHODH Q02127 1/20 0.38
CHRNB2 P17787 2/20 0.37
CHRNA4 P43681 2/20 0.37
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
CHRNA7 P36544 1/20 0.37
MAPT P10636 1/20 0.36
METAP2 P50579 2/20 0.36
TGFBR1 P36897 1/20 0.36
ITK Q08881 1/20 0.36
PRMT5 O14744 2/20 0.35
WDR77 Q9BQA1 1/20 0.35
ACHE P22303 2/20 0.35
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
PI4KA P42356 1/20 0.34
PIK3CG P48736 1/20 0.34
PI4KB Q9UBF8 1/20 0.34
BCHE P06276 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12059210 0.89 ACHE (0.43) CYP3A4DHODHCHRNB2CHRNA4CHRNB4
SCHEMBL6920560 0.79 POLB (0.43) NPC1RAB9ATDP1ABL1
SCHEMBL6922480 0.78 ACHE (0.44) CYP3A4DHODHMETAP2TGFBR1PRMT5
SCHEMBL14240280 0.77 ACHE (0.41) CYP3A4DHODHCHRNB2CHRNA4CHRNB4
SCHEMBL6920937 0.76 TGFBR1 (0.51) CYP3A4TGFBR1
SCHEMBL6922491 0.76 ACHE (0.43) CYP3A4DHODHMETAP2TGFBR1PRMT5
SCHEMBL6922402 0.76 CACNA2D1 (0.40) ACHEBCHENPC1RAB9A
SCHEMBL6922215 0.76 TGFBR1 (0.43) CYP3A4DHODHMETAP2TGFBR1PRMT5
SCHEMBL6920430 0.76 CYP3A4 (0.40) CYP3A4DHODHCHRNB2CHRNA4CHRNB4
SCHEMBL6922064 0.76 CYP3A4 (0.46) CYP3A4DHODHMAPTMETAP2TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-12-29 US disclosed
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof GRM5, GRM2, GRM1 CYP3A4 4447/4885DHODH 2339/4885CHRNB2 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.